From Detection to Cure: How Innovations and Collaborations Are Rewriting the Rare Disease Playbook

The term “rare disease” is a tragic paradox. While individual conditions may affect only a handful of patients, collectively they cast a shadow over hundreds of millions of lives worldwide. For decades, these patients and their families have been trapped in agonizing diagnostic odysseys—enduring years of medical uncertainty, limited treatment options, and a glaring lack of research investment. Seeking to rewrite this narrative, leading experts in genetic medicine and therapeutic development gathered at the Asia Summit on Global Health (ASGH) 2026 for the session, “From Detection to Cure: Accelerating Innovations for Rare Diseases.”

Chaired by Dr Brian Hon-yin Chung, Clinical Associate Professor at The University of Hong Kong and Chief Executive Officer (CEO) of the Hong Kong Genome Institute (HKGI), the panel opened on an optimistic note. “Today, advancements in genomics, gene and cell therapy, and AI-driven diagnostics are transforming the landscape, offering new hope for faster detection and more effective cures,” Dr Chung declared, setting the stage for a paradigm-shifting discussion.

The Diagnostic Revolution

The journey to curing any rare condition invariably begins with an accurate diagnosis. Dr Francesco Cutrale, Co-Founder and Chief Technology Officer (CTO) of Kulia Labs Inc., highlighted the monumental steps the industry has taken in genomic diagnostics. He recalled that back in 2008, a typical whole-genome sequencing (WGS) process took four weeks to complete and cost over a million dollars. Today, cutting-edge facilities like Rady Children’s Hospital can perform that same sequencing in less than 15 hours for under $200. This rapid turnaround provides actionable data for critically ill children in record time, acting as a crucial enabling achievement for the entire field. Dr Chung corroborated this progress, noting that clinical geneticists now routinely deploy genome sequencing to diagnose patients directly in intensive care units, bypassing months of clinical guesswork.

Bridging the Data Gap with Artificial Intelligence

Despite cheaper sequencing, diagnostic challenges persist due to extreme data scarcity. Dr Cutrale pointed out that 95% of rare diseases currently lack a treatment. While over 300 million people are living with at least one rare condition worldwide, only about 15 million of them have a treatment available. Furthermore, regional disparities severely restrict access; the Asia-Pacific region holds 30% of the patient population but hosts only 12% to 15% of clinical trials. 

To bridge this gap, innovators use artificial intelligence (AI) and natural language processing to extract features from clinical records and match patients to global trials. However, Dr Cutrale warned that AI risks hallucinating when trained on small sample sizes. He emphasized: “The challenge is data scarcity, and the solution is federated AI with global collaborations.”

Overcoming Delivery Challenges in RNA Technology

Once clinicians identify a defective gene, the next hurdle involves finding an effective cure. Professor Liang Zicai, Founder and Chairman of Suzhou Ribo Life Science, presented RNA therapeutics as one of the best solutions available today. He explained that the industry has traditionally targeted diseases at the protein level using small molecules or antibodies. “By shifting the target level from proteins… to mRNA, we increased the clinical success rate from 5 to 10% to 60%,” said Liang. This paradigm shift means drug developers almost guarantee success when they initiate just two programs, drastically lowering the historical development costs that previously soared up to $1.5 billion. Furthermore, targeting mRNA increases potential disease targets from roughly 600 to over 3,000, making rare diseases highly curable and affordable.

While RNA synthesis and manufacturing scale easily and cost-effectively, developers face significant scientific hurdles in drug delivery. Professor Liang noted that researchers have successfully cracked the code for delivering RNA to the liver using GalNAc conjugate technology, which targets hepatocytes safely and efficiently. This success explains the recent surge in RNA drugs for liver targets. However, many rare diseases originate in extrahepatic tissues, such as the muscle, central nervous system, heart, and eye. Consequently, the industry must develop novel delivery vehicles to safely transport RNA into these critical areas. Additionally, treating patients before irreversible damage occurs requires robust early detection systems, such as newborn screening, to maximize the effectiveness of these genetic interventions.

Accelerating Gene Therapies and Viral Vectors

Professor Leszek Lisowski, who leads the Translational Vectorology Unit at the Children’s Medical Research Institute, shared specialized perspectives on engineering viral vectors for next-generation gene therapies. He emphasized the extraordinary compression of therapeutic development timelines currently reshaping the industry. Historically, moving a drug from an initial concept to a Phase 1 clinical trial took 10 to 15 years. Nowadays, researchers can advance a new biologic or gene therapy into human studies in about three years. This speed acts as a game changer, as children with rare genetic diseases often progress too far or do not live long enough to benefit from traditional 10-year timelines. For the first time, researchers fulfill the 70-year-old promise of gene therapy by curing diseases rather than just alleviating symptoms.

Reflecting on this accelerated trajectory, Dr. Chung stressed that the clinical workforce must keep up with these advances in science. “The whole ecosystem has to move forward together. Beyond scientific progress, the clinical team, including doctors, nurses, and genetic counselors, have to understand the implications of a genetic diagnosis,” he remarked, highlighting the necessity of integrated growth across the healthcare spectrum.

Bridging Academia and Commercial Manufacturing

To sustain this rapid acceleration, the biopharma industry must bridge the profound gap between academic discovery and commercial scalability. Drawing on his expertise as the Chief Technology Officer of the Viral Vector Manufacturing Facility — an Australian CDMO offering design, development, and clinical-grade manufacturing services for recombinant lentiviral (rLV) and adeno-associated viral (rAAV) vectors — Professor Lisowski outlined a practical solution. He argued that while academia traditionally focuses on pure discovery and peer-reviewed publications, the pharma industry demands scalable products and market viability. Integrating a CDMO directly with an academic institution effectively solves this fundamental misalignment. 

Under this model, researchers take an academic discovery and immediately apply industry-standard manufacturing processes. They test how a newAAV capsid scales in a commercial bioreactor rather than merely publishing a journal paper and moving on. “Because if you have a brilliant vector that targets the brain but you can’t manufacture it at a reasonable titer, it’s useless for a product,” Professor Lisowski concluded. 

Revolutionizing Cell Therapies and Enhancing Accessibility

Dr Inna Menkova, Co-founder and CEO of Allogenica, brought a complementary perspective on advanced cell therapies. She noted that the first wave of chimeric antigen receptor (CAR) T-cell therapies profoundly modified outcomes for patients with rare blood cancers such as B-cell lymphomas. However, the current generation relies heavily on autologous processes, taking a patient’s own cells, shipping them to a centralized facility for modification, and returning them. This logistical nightmare takes weeks and incurs massive costs, creating a severe accessibility hurdle. Dr Menkova insisted that the field must urgently transition to allogeneic, “off-the-shelf” cell therapies.

Leveraging healthy donor material enables the engineering of therapies capable of evading immune rejection while mitigating the risk of graft-versus-host disease (GvHD). This approach allows companies to manufacture large batches at significantly reduced costs, keeping them frozen and ready for immediate patient use. To achieve true universality and secure regulatory approval, innovators need to refine genome editing precision to guarantee both the safety and consistency of these off-the-shelf interventions. Dr Menkova also highlighted an upcoming wave of in vivo cell therapies that bypass ex vivo manufacturing entirely by injecting engineered vectors directly into the human body. She offered strict advice to early-stage innovators: “Don’t develop a therapy in the lab that cannot be scaled up for commercial production.”

Fostering Open Science and Global Collaboration

Rute Fernandes, a Life Sciences Executive and Board Member of Conscience, emphasized that tackling smaller patient populations necessitates much larger global collaborations. She championed the concept of open science as a critical catalyst, especially in areas characterized by market failure where venture capital hesitates to tread. By openly sharing early-stage discovery data, researchers de-risk therapeutic targets for everyone. “We shouldn’t compete on basic science; we should compete on the final therapeutic product,” Fernandes argued. This open approach allows scientists around the world to test hypotheses without constantly “reinventing the wheel”. She also urged companies to engage early with payers, regulators, and pharmaceutical partners to build robust partnerships centered around transparent data sharing.

Regulatory Innovation and Adaptive Pathways

Accelerating rare disease innovation requires effective and adaptive regulatory pathways. Fernandes pointed out that conducting a phase 3 randomized, double-blind, placebo-controlled trial proves impossible and unethical for an ultra-rare disease that affects only 50 patients globally. Regulators must participate in the development journey early to define acceptable real-world evidence and patient registries. Fortunately, progress remains evident. Over 50% of the FDA novel drug approvals in 2023 received orphan drug designation. Europe has approved more than 300 orphan medicines, and mainland China has introduced treatments for over 200 diseases under its National Rare Disease Plan since 2018. The World Health Organization now urges all countries to integrate rare disease strategies into their national health plans.

Rethinking Financing and Affordability

Despite scientific triumphs, access remains the ultimate challenge for rare disease patients. Traditional reimbursement models fail to accommodate one-time, potentially curative therapies that cost millions of dollars. Fernandes called for innovative financing models, including outcomes-based agreements where payers only disburse funds if the drug works, or pay in installments based on continued efficacy. For ultra-rare diseases, individual countries often lack the patient numbers to justify a standard health technology assessment. Therefore, nations must form cross-border agreements, pooling resources and data to evaluate treatments and negotiate prices collectively. Society must also rethink how it values these therapies, factoring in the economic return of a patient re-entering society and caregivers returning to work.

Forging a Curative Future

The panelists concluded the session by sharing actionable advice for early-stage innovators. Professor Lisowski urged scientists to focus relentlessly on patient needs rather than falling in love with their proprietary technology. Dr Cutrale reminded data scientists to build algorithms that integrate seamlessly into a doctor’s daily clinical workflow. Professor Liang emphasized persistence, noting that drug development remains a long journey filled with failures. From the astonishing speed of AI-driven diagnostics to the curative promise of RNA, viral vectors, and off-the-shelf cell therapies, the rare disease landscape undergoes a profound transformation. By fostering cross-sector collaborations and innovative financing models, the global biopharma community can finally bring these life-changing breakthroughs to the patients who desperately need them.

Author

Richard Chau